Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease.
about
Mitochondrial Dysfunction in Alzheimer's Disease and the Rationale for Bioenergetics Based TherapiesThe Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer's Disease and Spinal Cord InjuryMitochondrial Dysfunction Contributes to the Pathogenesis of Alzheimer's DiseaseOxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventionsMitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic interventionMitochondrial dysfunction: different routes to Alzheimer's disease therapyRole of protein kinase A in regulating mitochondrial function and neuronal development: implications to neurodegenerative diseasesMitochondrial genome changes and neurodegenerative diseasesAfter the banquet: mitochondrial biogenesis, mitophagy, and cell survivalEstrogen amelioration of Aβ-induced defects in mitochondria is mediated by mitochondrial signaling pathway involving ERβ, AKAP and Drp1.Neuronal Gene Targets of NF-κB and Their Dysregulation in Alzheimer's DiseaseEstrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain DiseasesMitochondrial dysfunction in neurodegenerative diseasesGLP-1 improves neuropathology after murine cold lesion brain traumaPGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease.Cerebellar transcriptional alterations with Purkinje cell dysfunction and loss in mice lacking PGC-1α.AP39, a Mitochondria-Targeted Hydrogen Sulfide Donor, Supports Cellular Bioenergetics and Protects against Alzheimer's Disease by Preserving Mitochondrial Function in APP/PS1 Mice and NeuronsMitochondria in Alzheimer's Disease and Diabetes-Associated Neurodegeneration: License to Heal!Mitochondrial DNA damage in a mouse model of Alzheimer's disease decreases amyloid beta plaque formationMitochondrial Effects of PGC-1alpha Silencing in MPP+ Treated Human SH-SY5Y Neuroblastoma Cells.Mice lacking the transcriptional coactivator PGC-1α exhibit alterations in inhibitory synaptic transmission in the motor cortex.Diammonium glycyrrhizinate upregulates PGC-1α and protects against Aβ1-42-induced neurotoxicityA greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset.Mitochondrial dysfunction and cellular metabolic deficiency in Alzheimer's diseaseDevelopment of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Metabolic states following accumulation of intracellular aggregates: implications for neurodegenerative diseases.Upregulation of PGC-1α expression by Alzheimer's disease-associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APPThe hypothalamus in Alzheimer's disease: a Golgi and electron microscope study.Myeloid cell leukemia 1 (Mcl(-1)) protects against 1-methyl-4-phenylpyridinium ion (MPP+) induced apoptosis in Parkinson's disease.Role of mitochondrial homeostasis and dynamics in Alzheimer's disease.Electroacupuncture Upregulates SIRT1-Dependent PGC-1α Expression in SAMP8 Mice.Interneuron Transcriptional Dysregulation Causes Frequency-Dependent Alterations in the Balance of Inhibition and Excitation in Hippocampus.Abnormal Glucose Metabolism in Alzheimer's Disease: Relation to Autophagy/Mitophagy and Therapeutic ApproachesMitochondrial Alterations in Peripheral Mononuclear Blood Cells from Alzheimer's Disease and Mild Cognitive Impairment Patients.Different molecular mechanisms involved in spontaneous and oxidative stress-induced mitochondrial fragmentation in tripeptidyl peptidase-1 (TPP-1)-deficient fibroblasts.Overexpression of human selenoprotein H in neuronal cells enhances mitochondrial biogenesis and function through activation of protein kinase A, protein kinase B, and cyclic adenosine monophosphate response element-binding protein pathwayTolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjectsMitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseasesMolecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.Transcriptional regulation of insulin-degrading enzyme modulates mitochondrial amyloid β (Aβ) peptide catabolism and functionality.
P2860
Q26750081-95C7393B-EFA5-4D4B-AEB5-CBB23079DB4BQ26767879-44AE7A13-33F8-45FE-8E64-4640FEDFC1E0Q26801929-CF058651-6113-4262-B9CA-B570B52E9FB0Q26851676-23670F6F-8A89-4D92-A7A1-D29483E46B1AQ26865358-64051A5B-5DC8-4DDC-A5CA-DEA9BF3FB928Q27009475-1F7B2B2A-211D-4515-967D-5E42779ABC7BQ27021384-FA3595F8-7C38-46D6-9592-CCEEC1747C52Q27023750-C7908ECD-52A5-4FDF-95FC-ECB0A60686A0Q27026657-909DDA28-2278-4544-831F-0F8842863DECQ27324661-FC2AB8E1-6314-47FA-875E-C4B371DCAFF1Q28074504-C439471B-FA52-4291-BF0B-823C0AFCC645Q28079898-742D4C6E-0EE4-49F9-A221-5D92CAD681A0Q28387647-6173C142-3AF4-48F4-B472-D898D4F7281DQ28651569-6D05C492-B1A0-4654-92CC-3A02018895A3Q30574513-4F9A52BF-5CD9-4130-981A-CDF566CDCCF1Q30613057-FE84A3D3-8A64-4B39-8532-9602BA24249AQ31071777-ADA15188-CD95-41A0-8B5D-1FB8F29FADB1Q33364882-B46A553A-6A35-4B48-B3FE-1691AD45996AQ33608218-A837718E-D52A-4015-8906-D03181145C79Q33734894-C82678F7-2868-422B-8D95-0B9B85AD084BQ33799027-176F5F1A-CC95-42B8-B059-6B410AEDD537Q34249402-1C264599-A117-4822-84F2-650C4D905635Q34275231-05296C45-AA3F-45E1-9FFD-4EC2BA2883D3Q34299120-F78C9B35-4EC3-4E65-8F16-7742A6E8116AQ34538482-120DAFC0-A5B1-4655-B426-DB1B9115A766Q34718426-27464DDA-2EBE-4E84-B476-91037C36C079Q35093148-2CE93213-41C2-401A-BC2C-821093AE194AQ35404510-05E94FAF-E65D-4C0B-8CD7-5FC97C467E38Q35743031-68D9756E-C171-483C-9957-BE18CB007C13Q35916588-732EE736-ABDE-4E39-8D99-CB0C70F8DEA9Q36263721-48BE5A68-98E5-4561-BD74-ADA5B50EDE52Q36290045-CAD4058F-4444-4F3B-8D06-67AD98703874Q36359713-317BA042-BEC7-4956-A1E5-B17C503991F7Q36531568-960848E5-1458-41F5-9DBF-96AA568183B1Q36593242-58DC1311-0C68-485E-98E8-647DCD1B598DQ36599604-429D8AE5-5CBD-48A9-A845-4F14FF8C886FQ36751377-C91F7B2E-4D26-45BF-9580-F7FCF33B5314Q36771650-A8A2ACBC-9BDC-4E17-910D-1A7ABD2F66DFQ36771721-3A10860A-4224-4CEA-8594-98D98501978CQ36812453-54F4DDB0-FD79-43B2-9279-EA267297B839
P2860
Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Impaired mitochondrial biogene ...... nction in Alzheimer's disease.
@ast
Impaired mitochondrial biogene ...... nction in Alzheimer's disease.
@en
type
label
Impaired mitochondrial biogene ...... nction in Alzheimer's disease.
@ast
Impaired mitochondrial biogene ...... nction in Alzheimer's disease.
@en
prefLabel
Impaired mitochondrial biogene ...... nction in Alzheimer's disease.
@ast
Impaired mitochondrial biogene ...... nction in Alzheimer's disease.
@en
P2093
P2860
P50
P1476
Impaired mitochondrial biogene ...... nction in Alzheimer's disease.
@en
P2093
Baiyang Sheng
Gemma Casadesus
Hyoung-gon Lee
P2860
P304
P356
10.1111/J.1471-4159.2011.07581.X
P407
P577
2011-12-08T00:00:00Z